Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment
Chengqi Yu,1 Leilei Jiang,2 Dan Yang,2 Xin Dong,2 Rong Yu,2 Huiming Yu2 1School of Basic Medical Science, Capital Medical University, Beijing, 100069, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Onc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-10-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/anlotinib-hydrochloride-and-pd-1-blockade-as-a-salvage-second-line-tre-peer-reviewed-fulltext-article-OTT |
| _version_ | 1798030295066214400 |
|---|---|
| author | Yu C Jiang L Yang D Dong X Yu R Yu H |
| author_facet | Yu C Jiang L Yang D Dong X Yu R Yu H |
| author_sort | Yu C |
| collection | DOAJ |
| description | Chengqi Yu,1 Leilei Jiang,2 Dan Yang,2 Xin Dong,2 Rong Yu,2 Huiming Yu2 1School of Basic Medical Science, Capital Medical University, Beijing, 100069, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, People’s Republic of ChinaCorrespondence: Huiming Yu, Department of Radiation Oncology, Peking University Cancer Hospital & Institute, 52# Fucheng Road, Haidian District, Beijing, 100142, People’s Republic of China, Tel +86 13699249320, Fax +86 10-59300192, Email huiming740512@126.comPurpose: As for local advanced non-small cell lung cancer (NSCLC), synchronous radiotherapy and chemotherapy is the standard treatment mode. But for patients with progress in half a year, which means the second-line chemotherapy effect is not ideal for them. We observed the efficacy and safety of anlotinib hydrochloride combined with PD-1 blockade as the second-line treatment for those patients in this trial.Patients and Methods: From January 2018 to December 2019, 57 patients with the progress of local advanced NSCLC treated with anlotinib plus PD-1 blockade until disease progression or intolerance as a result of adverse events. Patients have been assessed using computed tomography prior to treatment and during follow-up every 2 months until disease progression or death. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety. Survival curves were created using the Kaplan–Meier method.Results: 57 patients were enrolled. The median age was 64 years, and 61.4% of the patients were men. The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell carcinoma, no brain or liver metastases had longer PFS than patients with liver metastasis. When the PFS was calculated from the time of second treatment, the median PFS was 9 months. Most adverse events (AEs) were grade 1– 3, one drug-related death was noted.Conclusion: The expected outcome of this study is that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, OS than second-line chemotherapy. The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment.Keywords: anlotinib, PD-1 blockade, local advanced non-small cell lung cancer, angiogenesis, immunotherapy |
| first_indexed | 2024-04-11T19:37:58Z |
| format | Article |
| id | doaj.art-ff81ed3a51b844358be3982877d6ff90 |
| institution | Directory Open Access Journal |
| issn | 1178-6930 |
| language | English |
| last_indexed | 2024-04-11T19:37:58Z |
| publishDate | 2022-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | OncoTargets and Therapy |
| spelling | doaj.art-ff81ed3a51b844358be3982877d6ff902022-12-22T04:06:47ZengDove Medical PressOncoTargets and Therapy1178-69302022-10-01Volume 151221122879019Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard TreatmentYu CJiang LYang DDong XYu RYu HChengqi Yu,1 Leilei Jiang,2 Dan Yang,2 Xin Dong,2 Rong Yu,2 Huiming Yu2 1School of Basic Medical Science, Capital Medical University, Beijing, 100069, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, People’s Republic of ChinaCorrespondence: Huiming Yu, Department of Radiation Oncology, Peking University Cancer Hospital & Institute, 52# Fucheng Road, Haidian District, Beijing, 100142, People’s Republic of China, Tel +86 13699249320, Fax +86 10-59300192, Email huiming740512@126.comPurpose: As for local advanced non-small cell lung cancer (NSCLC), synchronous radiotherapy and chemotherapy is the standard treatment mode. But for patients with progress in half a year, which means the second-line chemotherapy effect is not ideal for them. We observed the efficacy and safety of anlotinib hydrochloride combined with PD-1 blockade as the second-line treatment for those patients in this trial.Patients and Methods: From January 2018 to December 2019, 57 patients with the progress of local advanced NSCLC treated with anlotinib plus PD-1 blockade until disease progression or intolerance as a result of adverse events. Patients have been assessed using computed tomography prior to treatment and during follow-up every 2 months until disease progression or death. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety. Survival curves were created using the Kaplan–Meier method.Results: 57 patients were enrolled. The median age was 64 years, and 61.4% of the patients were men. The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell carcinoma, no brain or liver metastases had longer PFS than patients with liver metastasis. When the PFS was calculated from the time of second treatment, the median PFS was 9 months. Most adverse events (AEs) were grade 1– 3, one drug-related death was noted.Conclusion: The expected outcome of this study is that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, OS than second-line chemotherapy. The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment.Keywords: anlotinib, PD-1 blockade, local advanced non-small cell lung cancer, angiogenesis, immunotherapyhttps://www.dovepress.com/anlotinib-hydrochloride-and-pd-1-blockade-as-a-salvage-second-line-tre-peer-reviewed-fulltext-article-OTTanlotinibpd-1 blockadelocal advanced non-small cell lung cancerangiogenesisimmunotherapy. |
| spellingShingle | Yu C Jiang L Yang D Dong X Yu R Yu H Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment OncoTargets and Therapy anlotinib pd-1 blockade local advanced non-small cell lung cancer angiogenesis immunotherapy. |
| title | Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment |
| title_full | Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment |
| title_fullStr | Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment |
| title_full_unstemmed | Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment |
| title_short | Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment |
| title_sort | anlotinib hydrochloride and pd 1 blockade as a salvage second line treatment in patients with progress of local advanced non small cell lung cancer in half a year after standard treatment |
| topic | anlotinib pd-1 blockade local advanced non-small cell lung cancer angiogenesis immunotherapy. |
| url | https://www.dovepress.com/anlotinib-hydrochloride-and-pd-1-blockade-as-a-salvage-second-line-tre-peer-reviewed-fulltext-article-OTT |
| work_keys_str_mv | AT yuc anlotinibhydrochlorideandpd1blockadeasasalvagesecondlinetreatmentinpatientswithprogressoflocaladvancednonsmallcelllungcancerinhalfayearafterstandardtreatment AT jiangl anlotinibhydrochlorideandpd1blockadeasasalvagesecondlinetreatmentinpatientswithprogressoflocaladvancednonsmallcelllungcancerinhalfayearafterstandardtreatment AT yangd anlotinibhydrochlorideandpd1blockadeasasalvagesecondlinetreatmentinpatientswithprogressoflocaladvancednonsmallcelllungcancerinhalfayearafterstandardtreatment AT dongx anlotinibhydrochlorideandpd1blockadeasasalvagesecondlinetreatmentinpatientswithprogressoflocaladvancednonsmallcelllungcancerinhalfayearafterstandardtreatment AT yur anlotinibhydrochlorideandpd1blockadeasasalvagesecondlinetreatmentinpatientswithprogressoflocaladvancednonsmallcelllungcancerinhalfayearafterstandardtreatment AT yuh anlotinibhydrochlorideandpd1blockadeasasalvagesecondlinetreatmentinpatientswithprogressoflocaladvancednonsmallcelllungcancerinhalfayearafterstandardtreatment |